Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma

Phase 2

Completed

Conditions: Childhood Immunoblastic Large Cell Lymphoma
Childhood Diffuse Large Cell Lymphoma
Stage I Childhood Small Noncleaved Cell Lymphoma
Stage II Childhood Large Cell Lymphoma
Stage II Childhood Small Noncleaved Cell Lymphoma
Stage IV Childhood Small Noncleaved Cell Lymphoma
Stage I Childhood Large Cell Lymphoma
Stage III Childhood Large Cell Lymphoma
Stage IV Childhood Large Cell Lymphoma
Untreated Childhood Acute Lymphoblastic Leukemia

Interventions: Drug: doxorubicin hydrochloride
Drug: cyclophosphamide
Drug: methotrexate
Drug: leucovorin calcium
Drug: rasburicase
Drug: prednisone
Drug: methylprednisolone
Biological: filgrastim
Biological: rituximab
Drug: cytarabine
Drug: etoposide
Drug: vincristine sulfate
Drug: hydrocortisone sodium succinate
Other: laboratory biomarker analysis

First Posted Date: 2003-04-09

Last Posted Date: 2014-09-19

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 97

Registration Number: NCT00057811

Locations: 🇺🇸
Children's Oncology Group, Arcadia, California, United States

Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: darbepoetin alfa
Biological: filgrastim
Biological: rituximab
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: prednisone
Drug: vincristine sulfate
Radiation: indium In 111 ibritumomab tiuxetan
Radiation: yttrium Y 90 ibritumomab tiuxetan

First Posted Date: 2003-04-09

Last Posted Date: 2020-11-12

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 65

Registration Number: NCT00058422

Locations: 🇺🇸
M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Anti-Human CD45 Monoclonal Antibodies in Patients With Advanced Leukemia Prior to Allogeneic Stem Cell Transplantation

Phase 1

Completed

Conditions: LEUKEMIA

Interventions: Drug: CAMPATH-1H
Drug: Anti-CD45
Drug: Ara-C
Drug: Cyclophosphamide
Drug: Mesna
Radiation: Total Body Irradiation

First Posted Date: 2003-03-28

Last Posted Date: 2020-01-18

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 6

Registration Number: NCT00057005

Locations: 🇺🇸
The Methodist Hospital, Houston, Texas, United States
🇺🇸
Texas Children's Hospital, Houston, Texas, United States

Combination Chemotherapy in Treating Women With Stage I Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: cyclophosphamide
Drug: epirubicin hydrochloride
Drug: fluorouracil

First Posted Date: 2003-03-07

Last Posted Date: 2013-06-18

Lead Sponsor: UNICANCER

Target Recruit Count: 1512

Registration Number: NCT00055679

Locations: 🇫🇷
Institut Sainte Catherine, Avignon, France
🇫🇷
Polyclinique Bordeaux Nord Aquitaine, Boucher, France
🇫🇷
Centre Hospitalier Docteur Duchenne, Boulogne Sur Mer, France

and more 68 locations

Allogeneic Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer

Phase 2

Completed

Conditions: Kidney Cancer

Interventions: Procedure: allogeneic bone marrow transplantation
Biological: therapeutic allogeneic lymphocytes
Procedure: peripheral blood stem cell transplantation
Drug: cyclophosphamide
Drug: cyclosporine
Drug: fludarabine phosphate

First Posted Date: 2003-03-07

Last Posted Date: 2021-02-24

Lead Sponsor: UNICANCER

Target Recruit Count: 57

Registration Number: NCT00056095

Locations: 🇫🇷
Centre Paul Papin, Angers, France
🇫🇷
Centre Hospitalier Regional de Besancon - Hopital Jean Minjoz, Besancon, France
🇫🇷
Centre Hospitalier Regional et Universitaire d'Angers, Angers, France

and more 23 locations

Donor Umbilical Cord Blood Transplantation in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders

Phase 2

Completed

Conditions: Leukemia
Lymphoma
Myelodysplastic Syndromes
Myelodysplastic-Myeloproliferative Diseases

First Posted Date: 2003-03-07

Last Posted Date: 2011-03-07

Lead Sponsor: Roswell Park Cancer Institute

Registration Number: NCT00055653

Locations: 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
Children's Hospital of Orange County, Orange, California, United States
🇺🇸
North Shore University Hospital, Manhasset, New York, United States

and more 22 locations

Molecular Risk Assessment in Planning Treatment for Patients With Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

First Posted Date: 2003-03-07

Last Posted Date: 2010-06-10

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 9

Registration Number: NCT00055640

Locations: 🇺🇸
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Biological: Trastuzumab
Drug: Cyclophosphamide
Drug: docetaxel
Drug: Epirubicin
Drug: Fluorouracil

First Posted Date: 2003-02-06

Last Posted Date: 2013-07-19

Lead Sponsor: UNICANCER

Target Recruit Count: 3010

Registration Number: NCT00054587

Locations: 🇫🇷
Centre Hospitalier de Mulhouse, Mulhouse, France
🇫🇷
Institut Prive de Cancerologie, Grenoble, France
🇫🇷
Centre Paul Papin, Angers, France

and more 26 locations

Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer

Phase 2

Completed

Conditions: Leukemia
Lymphoma
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Diseases

Interventions: Drug: cyclophosphamide
Drug: busulfan
Radiation: radiation therapy
Drug: cytarabine
Drug: Etoposide
Procedure: Stem Cell Transfusion

First Posted Date: 2003-02-06

Last Posted Date: 2013-07-24

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 34

Registration Number: NCT00054327

Locations: 🇺🇸
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Combination Chemotherapy Compared With Observation After Surgery in Treating Women With Relapsed Nonmetastatic Breast Cancer

Phase 3

Terminated

Conditions: Breast Cancer

First Posted Date: 2003-02-06

Last Posted Date: 2014-12-16

Lead Sponsor: UNICANCER

Registration Number: NCT00053911

Locations: 🇫🇷
Clinique Claude Bernard, Albi, France
🇫🇷
Institut Bergonie, Bordeaux, France
🇫🇷
Centre Paul Papin, Angers, France

and more 23 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy